Utaswako Afp-L3
Payments companies reported to CMS as associated with Utaswako Afp-L3. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Utaswako Afp-L3, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Utaswako Afp-L3
These are the largest totals companies reported as associated with Utaswako Afp-L3. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Neil Mehta | San Francisco, CA | Hepatology | $10,464.60 |
| Gia Landry | Baton Rouge, LA | Gastroenterology (Internal Medicine) | $7,858.55 |
| Giorgio Roccaro | Atlanta, GA | Transplant Hepatology | $7,435.53 |
| Ju Dong Yang | West Hollywood, CA | Hepatology | $5,626.66 |
| Mitchell Shiffman | Newport News, VA | Gastroenterology (Internal Medicine) | $5,600.91 |
| Hrishikesh Samant | Shreveport, LA | Gastroenterology (Internal Medicine) | $3,810.44 |
| Rahul Maheshwari | Macon, GA | Transplant Surgery | $3,025.58 |
| Robert Gish | Folsom, CA | Hepatology | $2,800.00 |
| Anjana Pillai | Cleveland, OH | Gastroenterology (Internal Medicine) | $2,771.46 |
| Gabrielle Sanford | Shreveport, LA | Internal Medicine | $428.17 |
Prescribed Utaswako Afp-L3?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.